{"groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"FG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 milligrams (mg) was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"FG001","title":"Atezolizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"9"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"494"},{"groupId":"FG001","numSubjects":"485"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"36"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"83"}],"type":"Study Terminated By Sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"612"},{"groupId":"FG001","numSubjects":"613"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"579"},{"groupId":"FG001","numSubjects":"608"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"612"},{"groupId":"FG001","numSubjects":"613"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Twelve hundred and twenty-five participants were randomized in the study and were considered the Secondary Population (SP), out of which first 850 randomized participants were considered the Primary Population (PP)."}